pharmaand (pharmaand.com) Revenue and Competitors
Estimated Revenue & Valuation
- pharmaand (pharmaand.com)'s estimated annual revenue is currently $25.9M per year.
- pharmaand (pharmaand.com)'s estimated revenue per employee is $201,000
Employee Data
- pharmaand (pharmaand.com) has 129 Employees.
- pharmaand (pharmaand.com) grew their employee count by 416% last year.
pharmaand (pharmaand.com)'s People
Name | Title | Email/Phone |
---|---|---|
1 | Strategic Procurement Director | Reveal Email/Phone |
pharmaand (pharmaand.com) Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $44.2M | 220 | 6% | N/A | N/A |
#2 | $41.8M | 208 | 26% | N/A | N/A |
#3 | $25.3M | 126 | -5% | N/A | N/A |
#4 | $58.1M | 289 | 7% | N/A | N/A |
#5 | $25.9M | 129 | 416% | N/A | N/A |
#6 | $15.3M | 76 | 25% | N/A | N/A |
#7 | $21.1M | 105 | 72% | N/A | N/A |
#8 | N/A | 64 | 42% | N/A | N/A |
#9 | N/A | 59 | 48% | N/A | N/A |
#10 | $14.9M | 74 | 80% | N/A | N/A |
What Is pharmaand (pharmaand.com)?
pharma& is a privately owned company aiming at satisfying needs for unique, original, Specialty Care products in Europe. Our commitment to patient needs for well established original Specialty Care medicines and our Pan-European presence of own subsidaries, affliliated companies and partnerships secure sustainable product availibilty across all European markets. Headquartered in Vienna, in the Heart of Europe we deliver our products and reach patients across the entire European landscape. We are proud of our “every patient counts” commitment as well as of our strong partnership network.
keywords:N/AN/A
Total Funding
129
Number of Employees
$25.9M
Revenue (est)
416%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $32.1M | 131 | 14% | N/A |
#2 | $13.5M | 132 | 1% | N/A |
#3 | $19.1M | 132 | 27% | N/A |
#4 | $19.3M | 133 | 30% | N/A |
#5 | $28.1M | 134 | 12% | N/A |